News

Japan-based Otsuka Pharmaceutical has signed an agreement to acquire US-based Avanir Pharmaceuticals for $3.5bn. Otsuka, through its wholly-owned subsidiary Otsuka America, will acquire Avanir for $17 per share in cash. Otsuka will launch a...

Japan-based Daiichi Sankyo has signed an agreement with UCB Biopharma to jointly commercialise Lacosamide for the treatment of patients with epilepsy in Japan.   As part of the deal, UCB will manufacture and supply the product...

British-Swedish drugmaker AstraZeneca has signed a memorandum of understanding (MoU) to provide drug discovery facilities for Cancer Research UK at its new MRC UK Centre for Lead Discovery in Cambridge. As part of...

Hilleman Laboratories, a joint venture of Merck and Wellcome Trust, has signed a memorandum of understanding (MoU) with Bangladesh-based icddr,b and Incepta Vaccine to develop an oral cholera vaccine. The collaboration was established to fast track...

France-based pharmaceutical research company Servier has partnered with Intarcia Therapeutics to develop and commercialise its ITCA 650, outside the US and Japan. ITCA 650 is Intarcia's investigational therapy for the treatment of type 2 diabetes. The...

Bristol-Myers Squibb's (BMS) European medical education programme Partnering for Cure has selected four research projects, designed to investigate new ways to cure viral diseases. BMS will provide €300,000 to support the four research projects. The selected...

Cambridge, MA, USA and Krakow, Poland, November 7, 2014 / B3C newswire / -Felicitex Therapeutics, a leader in the diagnostics and development of therapeutics for quiescent cancers, and Selvita (PL: SLV), the largest drug discovery company in Central and...